Kenneth Waddell, NP
Nurse Practitioner · Forsyth, GANPI 1124504782
Payments from drug & device makers
Across 357 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$738
- Lilly USA, LLC$714
- Astellas Pharma US Inc$570
- AstraZeneca$559
- Otsuka America Pharmaceutical, Inc.$426
- AbbVie$386
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,08898%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $738 |
| Lilly USA, LLC | 45 | $714 |
| Astellas Pharma US Inc | 31 | $570 |
| AstraZeneca | 35 | $559 |
| Otsuka America Pharmaceutical, Inc. | 19 | $426 |
| AbbVie | 19 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $296 |
| Amgen | 17 | $267 |
| Boehringer Ingelheim | 14 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $205 |
| Phathom Pharmaceuticals, Inc. | 9 | $170 |
| Sumitomo Pharma America, Inc. | 16 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $153 |
| Pfizer | 8 | $133 |
| Noven Therapeutics, LLC | 8 | $133 |
| Corcept Therapeutics | 6 | $132 |
| Novartis | 6 | $130 |
| Exact Sciences | 7 | $120 |
| Lundbeck LLC | 4 | $99 |
| Dexcom, Inc. | 4 | $58 |
| Merck | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Antares Pharma, Inc. | 3 | $51 |
| Bayer | 2 | $43 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| GSK | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $32 |
| Ardelyx, Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Tris Pharma Inc | 1 | $25 |
| Halozyme Inc | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$6,182 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $83,828 |
| EliquisApixaban | 55 | $56,747 |
| FarxigaDapagliflozin Propanediol | 48 | $51,604 |
| MounjaroTirzepatide | 30 | $39,170 |
| JanuviaSitagliptin Phosphate | 39 | $33,493 |
| TrulicityDulaglutide | 14 | $30,052 |
| JardianceEmpagliflozin | 20 | $22,368 |
| XareltoRivaroxaban | 21 | $20,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,801 |
| VraylarCariprazine Hcl | 11 | $16,458 |
| TradjentaLinagliptin | 11 | $16,097 |
| LinzessLinaclotide | 11 | $14,060 |
| Repatha SureclickEvolocumab | 16 | $11,831 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,606 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $8,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $738 | $83,82857 claims |
| Lilly USA, LLCMounjaro, Trulicity | $714 | $69,22244 claims |
| PfizerEliquis, Dilantin | $133 | $59,45367 claims |
| AstraZenecaFarxiga, Symbicort | $559 | $55,81967 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $206 | $46,78145 claims |
| MerckJanuvia | $57 | $33,49339 claims |
| AbbVieVraylar, Linzess | $386 | $30,51822 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $41 | $24,16137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Forsyth
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.